<DOC>
	<DOC>NCT01915849</DOC>
	<brief_summary>The purpose of the study was to assess the effect of LIK066 on intestinal glucose absorption immediately after a single dose (immediate effect) and 6 hours following the dose (after multiple daily doses; sustained effect) in patients with type 2 diabetes mellitus (T2DM).</brief_summary>
	<brief_title>Effect of LIK066 on Glucose Absorption in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Patients, age 1865 years, must have been diagnosed with T2DM at least 6 months prior to screening with HbA1c 6.5 to 10.0%, inclusive, at screening. Fasting plasma glucose â‰¤250mg/dL at screening. If treated with metformin, patients must be on a stable dose for 12 weeks prior to randomization and maintain the dose until the end of the study. Patients with type 1 diabetes mellitus. Patients with history of acute diabetic complications within the 6 months prior to screening. Pregnant or nursing (lactating) women. Women of childbearing potential unless they are using effective methods of contraception during dosing of study treatment. Patients with signs or symptoms of significant diabetic complications. Patients treated with certain blood pressure or lipid lowering medications unless patients have been on stable doses for the 12 weeks prior to dosing. History of drug or alcohol abuse within the 12 months prior to dosing. Any surgical or medical condition, acute or unstable chronic disease which may, based on the investigator's opinion, jeopardize the patient in case of participation in the study. Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>